Cargando…

Beta‐blocker use and mortality among patients with systolic heart failure and pacemaker rhythm

AIMS: Beta‐blockers are proven to improve survival among patients with heart failure with reduced ejection fraction. Their efficacy in patients with heart failure with reduced ejection fraction and pacemaker devices has not been demonstrated. Our aim was to test the hypothesis that beta‐blocker ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perry, Andrew S., Maggioni, Aldo P., Tavazzi, Luigi, Levy, Wayne C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192283/ https://www.ncbi.nlm.nih.gov/pubmed/36999245 http://dx.doi.org/10.1002/ehf2.14353

Ejemplares similares

Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study
por: Pongiglione, Benedetta, et al.
Publicado: (2021)

Effect of Visit‐to‐Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the I (f) Inhibitor Ivabradine Trial (SHIFT) Trial
por: Böhm, Michael, et al.
Publicado: (2016)

Enoximone echocardiography: a novel test to evaluate left ventricular contractile reserve in patients with heart failure on chronic beta-blocker therapy
por: Ghio, Stefano, et al.
Publicado: (2003)

Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control
por: Wai, Bryan, et al.
Publicado: (2012)

The Impact of Treatment with Beta-Blockers upon Mortality in Chronic Heart Failure Patients
por: Taneva, Borjanka, et al.
Publicado: (2016)

Beta-blockers Associated with a Mortality Benefit in Patients with Systolic Dysfunction and Elevated Serum Bilirubin
por: Labos, Christopher, et al.
Publicado: (2014)

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
por: Borer, Jeffrey S., et al.
Publicado: (2012)

Beta-Blockers and Oxidative Stress in Patients with Heart Failure
por: Nakamura, Kazufumi, et al.
Publicado: (2011)

New advances in beta-blocker therapy in heart failure
por: Barrese, Vincenzo, et al.
Publicado: (2013)

Brachial pulse pressure in acute heart failure. Results of the Heart Failure Registry
por: Bonapace, Stefano, et al.
Publicado: (2019)

The effect of beta-blockers in acute heart failure according to heart rate
por: Kim, Hyun-Jin, et al.
Publicado: (2021)

Lower In‐Hospital Mortality With Beta‐Blocker Use at Admission in Patients With Acute Decompensated Heart Failure
por: Tamaki, Yodo, et al.
Publicado: (2021)

Poor tolerance of beta-blockers by elderly patients with heart failure
por: Yanagisawa, Satoshi, et al.
Publicado: (2010)

Beta Blockers in Heart Failure: More Evidence for an Old Friend
por: Baek, Sang Hong
Publicado: (2018)

Treatment optimization of beta-blockers in chronic heart failure therapy
por: Niriayo, Yirga Legesse, et al.
Publicado: (2020)

Implications of renin‐angiotensin‐system blocker discontinuation in acute decompensated heart failure with systolic dysfunction
por: Darden, Douglas, et al.
Publicado: (2019)

Association of digoxin with mortality and rehospitalization in heart failure patients treated with beta-blockers: Results from the Persian Heart Failure Patient Registry
por: Yazdi, Maryam, et al.
Publicado: (2022)

Adherence to beta‐blockers and long‐term risk of heart failure and mortality after a myocardial infarction
por: Desta, Liyew, et al.
Publicado: (2020)

Temporal trends in evidence supporting therapeutic interventions in heart failure and other European Society of Cardiology guidelines
por: Canepa, Marco, et al.
Publicado: (2023)

Leukocyte Redistribution: Effects of Beta Blockers in Patients with Chronic Heart Failure
por: von Haehling, Stephan, et al.
Publicado: (2009)

Beta-blocker therapy in elderly patients with renal dysfunction and heart failure
por: Martínez-Milla, Juan, et al.
Publicado: (2021)

Effects of Holding Beta-Blockers on the Vital Signs of Heart Failure Patients
por: Erickson, Marc, et al.
Publicado: (2021)

Beta-blockers and mechanical dyssynchrony in heart failure assessed by radionuclide ventriculography
por: Jones, K. A., et al.
Publicado: (2022)

Covariate balance in a Bayesian propensity score analysis of beta blocker therapy in heart failure patients
por: McCandless, Lawrence C, et al.
Publicado: (2009)

ACE-inhibitors, Beta-blockers or the Combination in Heart Failure: Is It Just an A–B–C ?: EDITORIAL to: Effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
por: de Boer, Rudolf A., et al.
Publicado: (2008)

Investigating the effects of beta-blockers on circadian heart rhythm using heart rate variability in ischemic heart disease with preserved ejection fraction
por: Saleem, Shiza, et al.
Publicado: (2023)

Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States
por: Borer, Jeffrey S., et al.
Publicado: (2016)

A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure
por: Iyngkaran, Pupalan, et al.
Publicado: (2016)

Beta-blocker Therapy at Discharge in Patients with Acute Heart Failure and Atrial Fibrillation
por: Ahn, Min-Soo, et al.
Publicado: (2020)

Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives
por: Chourdakis, Emmanouil, et al.
Publicado: (2021)

Using machine learning to uncover heterogeneity of beta blocker response in heart failure
por: Tison, Geoffrey H.
Publicado: (2022)

Effectiveness and safety of four different beta‐blockers in patients with chronic heart failure
por: Liu, Baoshan, et al.
Publicado: (2023)

Advances in systolic heart failure
por: Yuzefpolskaya, Melana, et al.
Publicado: (2010)

Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta‐blockers
por: Varian, Kenneth D., et al.
Publicado: (2020)

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker
por: Tan, Nicholas Y., et al.
Publicado: (2021)

Different Impact of Beta-Blockers on Long-Term Mortality in Heart Failure Patients with and without Chronic Obstructive Pulmonary Disease
por: Higuchi, Satoshi, et al.
Publicado: (2021)

β blockers for heart failure
por: Hoes, Arno W
Publicado: (2016)

The duration of beta‐blocker therapy and outcomes in patients without heart failure or left ventricular systolic dysfunction after acute myocardial infarction: A multicenter prospective cohort study
por: Wen, Xue‐Song, et al.
Publicado: (2022)

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
por: Mordi, Ify R., et al.
Publicado: (2019)

Disease-modifying medications in heart failure: more than ACE inhibitors and beta blockers
por: Chao, Chia-Ter
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_3nkmmsp7danqbmvfc8to8hka38